NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.22 +0.96 (+1.23%) GOLD FUTURES
2,342.90 -32.10 (-1.35%) DOW
39,442.39 -70.45 (-0.18%) Bitcoin GBP
49,921.59 +1,045.13 (+2.14%)
Akebia Therapeutics, Inc. (AX9.F)
| Previous close | 1.1500 |
| Open | 1.0920 |
| Bid | 1.1630 x 30000 |
| Ask | 1.1810 x 30000 |
| Day's range | 1.0920 - 1.0920 |
| 52-week range | 0.7410 - 2.8500 |
| Volume | |
| Avg. volume | 534 |
| Market cap | 228.878M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024. Akebia is launching Vafseo® (vadadustat) tablets, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months, which will be available in J
- PR Newswire
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
